IL160148A0 - Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor - Google Patents

Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor

Info

Publication number
IL160148A0
IL160148A0 IL16014802A IL16014802A IL160148A0 IL 160148 A0 IL160148 A0 IL 160148A0 IL 16014802 A IL16014802 A IL 16014802A IL 16014802 A IL16014802 A IL 16014802A IL 160148 A0 IL160148 A0 IL 160148A0
Authority
IL
Israel
Prior art keywords
metastasis
recurrence
inhibiting
preventing
pharmaceutical compositions
Prior art date
Application number
IL16014802A
Other languages
English (en)
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of IL160148A0 publication Critical patent/IL160148A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL16014802A 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor IL160148A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001249717 2001-08-21
PCT/JP2002/008309 WO2003015826A1 (fr) 2001-08-21 2002-08-16 Compositions pharmaceutiques comprenant des conjugues de polysaccharides permettant l'inhibition des metastases ou la prevention de la recurrence des tumeurs malignes

Publications (1)

Publication Number Publication Date
IL160148A0 true IL160148A0 (en) 2004-07-25

Family

ID=19078678

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16014802A IL160148A0 (en) 2001-08-21 2002-08-16 Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor

Country Status (18)

Country Link
EP (1) EP1418947A1 (fr)
KR (1) KR20040027972A (fr)
CN (1) CN100372570C (fr)
AR (1) AR035137A1 (fr)
AU (1) AU2002328093B2 (fr)
BR (1) BR0212036A (fr)
CA (1) CA2457056C (fr)
HU (1) HUP0401351A3 (fr)
IL (1) IL160148A0 (fr)
MX (1) MXPA04001599A (fr)
NO (1) NO20041194L (fr)
NZ (1) NZ530947A (fr)
PL (1) PL368319A1 (fr)
RU (1) RU2275913C2 (fr)
TW (1) TWI313609B (fr)
UA (1) UA75450C2 (fr)
WO (1) WO2003015826A1 (fr)
ZA (1) ZA200400917B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
FR2914305B1 (fr) 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
EP3693454A1 (fr) 2008-07-16 2020-08-12 Children's Medical Center Corporation Dispositif simulateur d'organe comportant des microcanaux et ses procédés d'utilisation et de fabrication
AU2012262139B2 (en) * 2011-06-02 2017-02-23 Children's Medical Center Corporation Methods and uses for ex vivo tissue culture systems
PL221351B1 (pl) 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych
KR102087017B1 (ko) 2012-10-11 2020-03-10 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
EP2910573B1 (fr) * 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Conjugué anticorps-médicament produit par liaison par l'intermédiaire d'un lieur ayant une structure hydrophile
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
TWI718144B (zh) 2015-05-04 2021-02-11 美商輝瑞股份有限公司 Ｂ型鏈球菌多醣－蛋白質軛合物、製造軛合物之方法、含軛合物之免疫原性組成物、及其用途
BR112017027690A2 (pt) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
EP3552626A4 (fr) 2016-12-12 2020-06-10 Daiichi Sankyo Company, Limited Association d'un conjugué anticorps-médicament et d'un inhibiteur de point de contrôle immunitaire
JP6679762B2 (ja) 2017-01-17 2020-04-15 第一三共株式会社 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
CN117838880A (zh) 2017-08-31 2024-04-09 第一三共株式会社 制备抗体-药物缀合物的新方法
EP3677589A4 (fr) 2017-08-31 2021-04-21 Daiichi Sankyo Company, Limited Procédé amélioré de production d'un conjugué anticorps-médicament
CN117815404A (zh) 2018-05-18 2024-04-05 第一三共株式会社 抗-muc1抗体-药物缀合物
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0640622T3 (da) * 1993-02-26 2000-10-23 Drug Delivery System Inst Ltd Polysaccharidderivat og lægemiddelbærer
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (fr) * 1995-12-28 2004-04-20 Kenji Tsujihara Derives de la camptothecine
WO1997038727A1 (fr) * 1996-04-15 1997-10-23 Asahi Kasei Kogyo Kabushiki Kaisha Composite medicamenteux
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CN1058038C (zh) * 1996-12-31 2000-11-01 中国科学院感光化学研究所 低收缩性光固化涂层材料及其制法和用途
EA003398B1 (ru) * 1998-05-22 2003-04-24 Дайити Фармасьютикал Ко., Лтд. Лекарственный комплекс c полимерным носителем

Also Published As

Publication number Publication date
CA2457056A1 (fr) 2003-02-27
ZA200400917B (en) 2004-08-25
RU2004108141A (ru) 2005-04-20
AU2002328093B2 (en) 2005-05-05
CN1545423A (zh) 2004-11-10
PL368319A1 (en) 2005-03-21
KR20040027972A (ko) 2004-04-01
NO20041194L (no) 2004-03-19
CA2457056C (fr) 2008-07-22
TWI313609B (en) 2009-08-21
NZ530947A (en) 2006-04-28
BR0212036A (pt) 2004-08-17
CN100372570C (zh) 2008-03-05
MXPA04001599A (es) 2004-07-08
UA75450C2 (en) 2006-04-17
EP1418947A1 (fr) 2004-05-19
AR035137A1 (es) 2004-04-14
WO2003015826A1 (fr) 2003-02-27
RU2275913C2 (ru) 2006-05-10
HUP0401351A3 (en) 2011-02-28
HUP0401351A2 (hu) 2004-12-28

Similar Documents

Publication Publication Date Title
IL160148A0 (en) Pharmaceutical compositions comprising polysaccharide conjugates for inhibiting the metastasis or preventing the recurrence of malignant tumor
AU3491001A (en) Compositions and methods for the early diagnosis of ovarian cancer
EP1257287A4 (fr) Compositions et methodes permettant le depistage precoce du cancer de l'ovaire
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU2002360769A1 (en) Breast cancer expression profiling
PL354540A1 (en) Drugs for the treatment of malignant tumours
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
EP1709152A4 (fr) Signature moleculaire du suppresseur de tumeur pten
IL164896A (en) Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors
AU9684601A (en) Compositions that inhibit proliferation of cancer cells
EP1476067A4 (fr) Compositions et procedes contre le cancer
AU2002246519A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
EP1461033A4 (fr) Methodes et compositions permettant de diminuer les effets indesirables de la chimiotherapie
AU2002257033A1 (en) Agents and methods for the prevention of initial onset and recurrence of existing cancers
AU2002341749A1 (en) Methods and compositions for inhibiting the proliferation of prostate cancer cells
HUP0402341A3 (en) Compositions containing thiazol-2-ylamines for the treatment of cancer
EP1349485A4 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
GB0110847D0 (en) Breast cancer detection
HK1068277A1 (en) Pharmaceutical compositions comprising chelidonineor derivatives thereof
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1487983A4 (fr) Prevention de recurrence et de metastase cancereuses
HUP0300772A3 (en) Medicament for the immunotherapy of malignant tumours
AU2003270202A8 (en) Pharmaceutical compositions useful for the treatment of cancers
HUP0302629A3 (en) Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
EP1459754A4 (fr) Medicaments pour la prevention et le traitement du cancer